pomalidomide,dexamethasone,isatuximab
sanofi,bms
on day 2 at #ims2022 we received updates on trials presented at previous meetings, including maintenance treatment following asct for newly diagnosed #myeloma patients and the use of sarclisa-pd as a standard-of-care therapy for rrmm. more details here: 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.